Literature DB >> 34037225

Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.

Quazim A Alayo1,2, Aava Khatiwada3, Anish Patel4, Maria Zulfiqar5, Anas Gremida1, Alexandra Gutierrez1, Richard P Rood1, Matthew A Ciorba1, George Christophi1,6, Parakkal Deepak1.   

Abstract

Entities:  

Keywords:  biologics; combination therapy; inflammatory bowel disease; tofacitinib

Mesh：

Substances：

Year:  2021        PMID： 34037225      PMCID： PMC8682277          DOI： 10.1093/ibd/izab112

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   7.290


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.

Authors:  Edward Yang; Nicola Panaccione; Natalie Whitmire; Parambir S Dulai; Niels Vande Casteele; Siddharth Singh; Brigid S Boland; Angelina Collins; William J Sandborn; Remo Panaccione; Robert Battat
Journal:  Aliment Pharmacol Ther       Date:  2020-04-24       Impact factor: 8.171

2.  The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study.

Authors:  Kerri Glassner; Ayah Oglat; Antonio Duran; Pramoda Koduru; Caroline Perry; Amanda Wilhite; Bincy P Abraham
Journal:  J Dig Dis       Date:  2020-06-11       Impact factor: 2.325

3.  Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.

Authors:  Joy A Lee; Pooja R Magavi; Gauree G Konijeti
Journal:  Inflamm Bowel Dis       Date:  2020-10-23       Impact factor: 5.325

4.  Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.

Authors:  Catherine Le Berre; Damien Loeuille; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-13       Impact factor: 11.382

5.  Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.

Authors:  Lukasz Kwapisz; Laura E Raffals; David H Bruining; Darrell S Pardi; William J Tremaine; Sunanda V Kane; Konstantinos A Papadakis; Nayantara Coelho-Prabhu; John B Kisiel; Valerie Heron; William A Faubion; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2020-02-14       Impact factor: 11.382

Review 6.  Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Authors:  L Vuitton; L Peyrin-Biroulet; J F Colombel; B Pariente; G Pineton de Chambrun; A J Walsh; J Panes; S P L Travis; J Y Mary; P Marteau
Journal:  Aliment Pharmacol Ther       Date:  2017-01-23       Impact factor: 8.171

7.  Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.

Authors:  Ingrid Ordás; Jordi Rimola; Ignacio Alfaro; Sonia Rodríguez; Jesús Castro-Poceiro; Anna Ramírez-Morros; Marta Gallego; Àngel Giner; Rebeca Barastegui; Agnès Fernández-Clotet; Maica Masamunt; Elena Ricart; Julián Panés
Journal:  Gastroenterology       Date:  2019-04-03       Impact factor: 22.682

8.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.

Authors:  Edward Shelton; Jessica R Allegretti; Betsy Stevens; Matthew Lucci; Hamed Khalili; Deanna D Nguyen; Jenny Sauk; Cosmas Giallourakis; John Garber; Matthew J Hamilton; Michal Tomczak; Fredrick Makrauer; Robert B Burakoff; Jonathan Levine; Punyaganie de Silva; Sonia Friedman; Ashwin Ananthakrishnan; Joshua R Korzenik; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

9.  Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.

Authors:  Parakkal Deepak; Quazim A Alayo; Aava Khatiwada; Bixuan Lin; Marc Fenster; Christina Dimopoulos; Geoffrey Bader; Roni Weisshof; Michael Jacobs; Alexandra Gutierrez; Matthew A Ciorba; George P Christophi; Anish Patel; Robert P Hirten; Jean-Frederic Colombel; David T Rubin; Christina Ha; Poonam Beniwal-Patel; Ryan C Ungaro; Gaurav Syal; Joel Pekow; Benjamin L Cohen; Andres Yarur
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-03       Impact factor: 13.576
  9 in total
  2 in total

1.  Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.

Authors:  Quazim A Alayo; Marc Fenster; Osama Altayar; Kerri L Glassner; Ernesto Llano; Kindra Clark-Snustad; Anish Patel; Lukasz Kwapisz; Andres J Yarur; Benjamin L Cohen; Matthew A Ciorba; Deborah Thomas; Scott D Lee; Edward V Loftus; David I Fudman; Bincy P Abraham; Jean-Frederic Colombel; Parakkal Deepak
Journal:  Crohns Colitis 360       Date:  2022-02-10

Review 2.  Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.

Authors:  Eleanor Liu; Nasar Aslam; Gaurav Nigam; Jimmy K Limdi
Journal:  Drugs Context       Date:  2022-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.